{
    "organizations": [],
    "uuid": "c9bab20e4d4de6ab328d8f209daf95856562f3db",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sumitomo-dainippon-pharma-unit-say/brief-sumitomo-dainippon-pharma-unit-says-positive-topline-results-from-study-of-apomorphine-sublingual-film-idUSL4N1PP1HA",
    "ord_in_thread": 0,
    "title": "BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd\n* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinsonâ€™s disease (PD) who experience motor fluctuations (OFF episodes)\n* Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants\nSource text in Japanese: goo.gl/sE7Qks\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-30T10:17:00.000+02:00",
    "crawled": "2018-01-30T18:43:01.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sumitomo",
        "dainippon",
        "pharma",
        "co",
        "ltd",
        "say",
        "unit",
        "sunovion",
        "pharmaceutical",
        "sunovion",
        "announced",
        "topline",
        "result",
        "pivotal",
        "phase",
        "randomized",
        "clinical",
        "trial",
        "evaluated",
        "apomorphine",
        "sublingual",
        "film",
        "patient",
        "parkinson",
        "disease",
        "pd",
        "experience",
        "motor",
        "fluctuation",
        "episode",
        "study",
        "met",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "medicine",
        "also",
        "generally",
        "study",
        "participant",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}